**Paederia foetida** Linn. leaf extract: an antihyperlipidemic, antihyperglycaemic and antioxidant activity

Vikas Kumar1*, Firoz Anwar2, Danish Ahmed1, Amita Verma1, Aftab Ahmed3, Zoheir A Damanhour4, Vatsala Mishra5, Pramod W Ramteke6, Prakash Chandra Bhatt7 and Mohd Mujeeb7*

**Abstract**

**Background:** The primary objective of the present investigation is to evaluate the antidiabetic, antihyperlipidemic and antioxidant activity of the methanolic extract of the *Paederia foetida* Linn. (*PF*) leaf extract in the streptozotocin induced diabetic rats.

**Methods:** Single intraperitoneal injection (IP) of streptozotocin (60 mg/kg body weight) was used for induction of diabetes in Swiss albino (wistar strain) rats. The induction of diabetes was confirmed after 3 days as noticing the increase in blood sugar level of tested rats. *PF* at a once a daily dose of 100 mg/kg, 250 mg/kg, 500 mg/kg, p.o. along with glibenclamide 10 mg/kg, p.o. was also given for 28 days. On the 28th day rats from all the groups fasted overnight and the blood was collected from the puncturing the retro orbit of the eye under mild anesthetic condition. There collected blood sample was used to determine the antihyperlipidemic, hypoglycemic and antioxidant parameters.

**Results:** The oral acute toxicity studies did not show any toxic effect till the dose at 2000 mg/kg. While oral glucose tolerance test showed better glucose tolerance in tested rats. The statistical data indicated that the different dose of the *PF* significantly increased the body weight, hexokinase, plasma insulin, high density lipoprotein cholesterol, superoxide dismutase, catalase and glutathione peroxides. It also decreases the level of fasting blood glucose, total cholesterol, triglycerides, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, malonaldehyde, glucose-6-phosphate, fructose-1-6-biphosphate and glycated hemoglobin in STZ induced diabetic rats. The histopathology of STZ induce diabetic rats, as expected the test dose of *PF* extract considerably modulates the pathological condition of various vital organ viz. heart, kidney, liver, pancreas as shown in the histopathology examinations.

**Conclusions:** Our investigation has clearly indicated that the leaf extract of *Paederia foetida* Linn. showed remarkable antihyperglycemic activity due to its possible systematic effect involving in the pancreatic and extra pancreatic mechanism. Forever, the antihyperlipidemic activity was exerted possible by lowering the higher level of lipid profile and decreasing the intercalated disc space in the heart. The antioxidant activity of extract was due to inhibition of lipid peroxidation and increasing the SOD, GPx and CAT. It was corroborate that the extract shown the *Paederia foetida* Linn leaves potential to be act as antidiabetic, antihyperlipidemic and antioxidant properties.

**Keywords:** *Paederia foetida*, Antihyperlipedemic, Hexokinase, Antioxidative

---

*Correspondence: phvikas@gmail.com; mohdmujeeb72@gmail.com*

1Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom Institute of Agriculture, Technology & Sciences (SHIATS)-Deemed University, Allahabad, Uttar Pradesh 211007, India

2Department of Phytochemistry & Pharmacognosy, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India

Full list of author information is available at the end of the article

© 2014 Kumar et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Diabetes mellitus (DM) is a condition in which the amount of glucose increases in the blood, because organs viz. adipose tissues and liver does not properly utilize the glucose. DM occurs due to hereditary and environmental causes, resulting in abnormally high blood sugar level [1,2]. The role of the insulin in the body is to release after a meal from the pancreas and stimulate the fat cells and muscle to remove the glucose from the blood and stimulate the liver to metabolize glucose, causing the blood sugar level to decrease to normal level. According to the WHO (World Health Organization) an estimated 300 million during World, 57.2 million adults in India affected in the year 2025 [3,4]. DM is the most common manifestation of metabolic disorder occurs in human due to the high consumption of carbohydrates and lipids [5]. Hyperglycaemia an associate with hyperlipidemia in the late phase of life is also prone to diabetes [6]. It is the complex metabolic endocrine disorder which resulting from disequilibrium of dynamic expression, causing the macro (heart attack, stroke and peripheral vascular disease) and micro (retinopathy, neuropathy and nephropathy) vascular complications [7,8]. Further, increase in the blood glucose level in diabetic patient causes alteration in utilization of glucose in the vital organs viz. adipose tissues and liver of the body. Increased in blood glucose level continuously generating reactive oxygen species (ROS) and superoxide anions, which further aggravate the diabetic complication by damaging the protein, deoxyribosenucleic acid and carbohydrate, which leading to increasing the oxidative stress [9-12]. The concentration of free radical production could be favorably reduced through appropriate dietary intake and drug therapy and thus less chance of diabetes and diabetic associated CVS disorder. Since there is no current treatment available for hypoglycemic, hypolipidemic and antioxidant drug together therefore, researchers are continuously working on discovery of effective drug to exert the action on hyperglycemia, hyperlipidemia and antioxidant effect with minimal or no signs of side or toxic effects.

Medicinal plants play as important role in the discovery of new counteractive agents and received much more attention as a source of biologically active substance including antioxidant, antihyperglycemic and antihyperlipidemic agents [13]. Since few decades, plants were used to treat diabetes and its complications. 400 plants and there 700 recipes in the formulation were used for the treatment of diabetes [14]. Consequently, modern medical science explores this fruitful field and thus discovered a first clinically used drug of its own kind from to treat diabetes i.e. metformin (Galega officinalis). By above investigation and the role of plant in generation of antidiabetic agents [15]. Present investigation carried out to evaluate the antidiabetic, antihyperlipidemic and antioxidant stress activity of Paederia foetida Linn.

Paederia foetida Linn. Belonging to family Rubiaceae, commonly known as Ghandhali in across the India and usually found upto an altitude 1800 m in Himalaya region. in folklore system of medicine it was indicated for the treatment of gout, diarrhea, piles, dysentery, calculi, stomachic, emetic, ulcers and different type of inflammations [16-19]. It has also been reported for antinociceptive [20], antiviral [21], antiarrhoeal [22], anti tussive [23], anti-inflammatory [24] and anti cancer activity [25]. It was reported that majority of chemical constituents were found in leaves of Paederia foetida Linn., these chemical constituents comprise of iridoid glycoside, sitosterol, alkaoids, carbohydrates, β-sitosterol, ascorbic acid, flavonoids, amino acids, stigmosterol, D/L galacturonic acid and volatile oil Paederia foetida Linn. [26-28]. The aim of the present study was to evaluate the antidiabetic, antihyperlipidemic and antioxidant activity of the methanolic extract of the Paederia foetida Linn. (PF) leaf extract in the STZ induced diabetic rats.

Methods

Plant materials

Fresh leaves of Paederia foetida Linn. was collected from Herbal garden, Department of Life Sciences, Dibrugarh University, Dibrugarh, Assam, India and authenticated by the Botanical Survey of India, Shillong, India. A voucher specimen (Ref. No.DU/PSc/HRB-2/08) was deposited for future reference.

Preparation of crude extracts

The collected leaves of PF were gently washed with tap water to remove the extraneous matter. After rinsing, the leaves were dried in shade at room temperature. The leaves were grounded and approximately 2 kg leaves were extracted with methanol in a Soxhlet apparatus for 5 days. The filtrate obtained after filtration of above mentioned extract was concentrated under reduced pressure at 4°C using rotatory evaporator until the extra solvent completely disappear resulting the crude semisolid residue (percentage yield, 30%). The resulting product was then stored at 4°C until further use. To carry out animal studies of this product, it was dissolved in 2% solution of CMC (Carboxyl methyl cellulose) in distilled water [28-30].

Extract standardization by HPTLC technique

Preparation of standard and sample solution

A stock solution of quercetin and ascorbic acid was prepared by dissolving 10 mg of standard quercetin in 10 mL of methanol (1000 μg/mL) and used as standard. The sample solution was prepared by extracting 2.0 g of dried powdered crude drug with 50 mL of methanol. The methanolic extract was filtered through the Whatman filter paper and
evaporated to dryness under reduced pressure. The residue obtained was re-dissolved in 1.0 mL of methanol and used for chromatography.

**HPTLC instrumentation and procedure**

The sample was carefully spotted in the precoated silica gel aluminum plate 60 F-254 (10 cm x 10 cm with 0.2 mm thickness, E. Merck, Germany) using a Camag Linomat V (Switzerland) in the form of the bands of width 4.0 mm with a Camag microliter syringe with 150 nL/s constant application rate. A constant application rate 150 nL/s was employed. The slit dimension was kept at 0.45 mm and 20 mm/s scanning speed was employed. The mobile phase was composed of hexane:ethyl acetate:formic acid (5:4:1, v/v/v). The development of the HPTLC plate was carried out in ascending manner in twin trough glass chamber. The saturation time for the mobile phase 20 min in the saturation chamber and chromatogram was developed up tot the length 80 mm of the HPTLC plate and dried in the room temperature. The scanning was done in absorbance mode up to 570 nm.

**Animals**

Healthy albino rats (Wistar strain) weight about 150-200 g were used. The entire animals used in the studies were kept in individual polyethylene cages and maintained standard condition (12 h dark and 12 h light circle; 25 ± 5°C; 40-60% humidity). The animals treated with standard fed *ad libitum* with normal laboratory chow standard pellet diet, purchased from the Hindustan Liver Limited, Mumbai, India. The animals were allowed to acclimate for 7 days before starting the experiments. All the studies were conducted in accordance with the Animal Ethical Committee as constituted by Siddhartha Institute of Pharmacy and the experimental protocol was approved by the Institutional Animal Ethical Committee of Siddhartha Institute of Pharmacy (1435/PO/a/11/CPCSEA).

**Oral acute toxicity studies**

For determination the oral acute toxicity studies the animals were starved overnight (16 h) and divided into six group (n = 6). Entire groups of tested animals received graded doses of *PF* extract dose raising level 100-2000 mg/kg body weight (i.e. 100, 250, 500, 1000, 2000 mg/kg body weight) and the animal was observed continuously for 2 h for on the basic of the following parameter after dosing [31,32]. The control group rats received vehicle only.

1. Behavioral changes viz., restlessness, irritability, alertness and fearfulness
2. Neurological changes viz., spontaneous activity, touch response, reactivity, pain response and gait
3. Autonomic changes viz., urination and defecation

These treatments observed for any changes and contraindication, death occurs during 24 h and 72 h.

**Effect of *PF* extract on glucose-hyperglycaemias animal model (glucose-loaded model, oral glucose tolerance test, OGTT)**

This test was performed on overnight (16 h) famished normal albino wistar rat. The rats were randomly divided into seven groups and each group having 6 rats, while, [33].

- **Group I:** rats was treated with vehicle only
- **Group II:** rats was treated with vehicle only + *PF* extract 500 mg/kg body weight
- **Group III:** rats was treated with vehicle only + Glucose 2 g/kg body weight
- **Group IV:** rats was treated with *PF* extract 100 mg/kg body weight
- **Group V:** rats was treated with *PF* extract 250 mg/kg body weight
- **Group VI:** rats was treated with *PF* extract 500 mg/kg body weight, and last group
- **Group VII:** rats treated with Glibenclamide 10 mg/kg body weight

After giving the respective option for the groups of the rats at mention above a single dose of 2 mg/kg of glucose was given to all the group after 30 min of initial feeding except group I and group II. Blood was drawn from the tail vein at regular intervals of time 0, 30, 60, 90, 120 and 150 min, blood glucose level were analyzed by the GOD-POD kit (Span diagnostic) following the given instruction by the manufacturer.

**Induction of diabetes**

Swiss albino (wistar strain) rat was used for the induction of diabetes. Before the experimentation performs all animals were starving overnight (16 h). Diabetes was induced by single intraperitoneal injection (i.p.) of streptozotocin (60 mg/kg body weight) prepared by streptozotocin dissolving in 0.1 M citrate buffer (pH = 4.5). All groups animal received the dose of STZ (60 mg/kg body weight) except normal control and normal control + *PF* (500 mg/kg) group rats. After 5 days all the groups’ animal blood samples collected from the puncturing the retro-orbits of the rat eyes and determine the blood glucose level using the GOD-POD method following the given instruction by the manufacture. The diabetes was confirmed by the elevating the blood glucose levels (220 mg/dl) were utilized for the study [34].

**Experiment with design**

After successfully developing the diabetes animals were divided into seven groups and each group contain six rats.
Group I: normal control rats administered vehicle only
Group II: normal control rats administered PF extract 500 mg/kg body weight
Group III: diabetic control rats administered drinking water alone
Group IV: tested rats administered PF extract 100 mg/kg body weight
Group V: tested rats administered PF extract 250 mg/kg body weight
Group VI: tested rats administered PF extract 500 mg/kg body weight
Group VII: tested rats administered glibenclamide 10 mg/kg body weight

All group rats received different doses of PF extract and glibenclamide using intragastric tube once daily for 28 days, continuously [35]. The blood samples of each animal were collected from the puncturing retro-orbital plexus and preserve anticoagulating agents; blood sample was centrifuged at 4000 RPM at 25°C for 15 min and analyzed for various biochemical parameters. The plasma insulin level was assayed by the radio-immunoassay method. All group rats serum glucose analysis was done by glucose oxidase-peroxidase (GOD-POD) method using Glucose estimation kit (Span Diagnostic, India). Other serum estimation done by spectrophotometrically using standard kit and following the given instruction. Serum triglyceride, total cholesterol, HDL (High Density Lipoprotein) cholesterol was analyzed by standard kits (Span Diagnostic, India) and other LDL (Low Density Lipoprotein) cholesterol [36], VLDL (Very Low Density Lipoprotein) were estimated with the help of the following formulas.

\[
\text{LDL} = \frac{\text{TC}}{1.19} + \frac{\text{TG}}{1.9} - \frac{\text{HDL}}{1.18} - 38 (\text{mg/dL})
\]

\[
\text{VLDL} = \frac{\text{triglycerides(mg/dL)}}{5}
\]

Estimation of antioxidant enzymes
For the estimation of the antioxidant enzymes, all groups rats’ liver successfully removed and homogenate. Liver homogenate prepared with ice chilled 10% potassium chloride solution, was used to measure the levels and activities of superoxide dismutase (SOD) [37], catalase (CAT) [38], glutathione peroxidase (GPx) and Malondialdehyde (MDA) by the method of [39,40].

Histopathology
At the end of the study 28 days all the groups animal were sacrificed under using mild anesthesia and isolated the different organ (heart, liver, pancreas and liver) of the animal for histopathology. All the animals were tested for absolute and relative organ weight and gross pathological lesions. The isolated organ (heart, liver, pancreas and liver)
tissue fixed at 40% natural buffered formalin, dehydrated by passing through a graded series of alcohol, and embedded in paraffin blocks and 5 mm sections were developed using a semi-automated rotatory microtome. Hematoxylin and eosin were used for staining [40].

Statistical analysis of experimental data
Values were presented as means ± standard error of the mean (S.E.M.). Statistical differences between the treatments and the controls were tested by one-way analysis of variance (ANOVA) followed by the Dennett’s test using the “Graph Pad Prism” statistic computer program. A difference in the mean values of p < 0.001 was considered to be statistically significant. Inhibition percentages were computed as follows:

\[
\% \text{ inhibition} = \frac{\text{Control} - \text{test control}}{\text{Control}} \times 100
\]

Result
HPTLC analysis
The HPTLC finger print result for methanolic extract of PF showed the three phytoconstituents and corresponding the \( R_f \) values start from the 0.3 to 0.93 (Figure 1).

The HPTLC analysis of PF extract showed the compound with \( R_f \) 0.77 as ascorbic acid as compared to the standard HPTLC graph of ascorbic acid (Figure 2).

Acute oral toxicity study in rats
Oral acute toxicity study, different doses of PF treated groups animals did not show any change in the behavioural, anatomical and neurological pattern. In complete study all the groups’ animals did not indicate any changes in the body weight and food consumption when compared to the vehicle treated groups. Therefore, it was concluded that the dose up to 2000 mg/kg of the PF extract was safe for the use.

Effect of PF on oral glucose tolerance test
The consequence of the acute effect of graded doses of PF extract on blood sugar level of normal healthy rats and glucose loaded were presented in the Figure 3. Oral administration of different doses of PF extract and glibenclamide significantly decline (\( P < 0.001 \)) the rise in blood glucose levels, after glucose administration. After loading the glucose, it was observed that glucose control group rats showed the higher AUC\(_{\text{glucose}}\) values (Figure 3). Oral administration of the different doses of the PF (100, 250

---

Figure 2 High performance thin liquid chromatography profiles of standard Ascorbic acid.
and 500 mg/kg) showed significantly (P < 0.001) lower AUC glucose values as compared to the glucose control group rats (Table 1).

**Effect of PF on blood glucose level**

The antidiabetic effect of repeated oral administration of PF leaves extract on STZ (streptozotocin) induced diabetic rats was presented in Table 2. Three different doses of PF leaves extract (100, 250 and 500 mg/kg) to STZ induced diabetic rats caused significantly (P < 0.001) decline the blood glucose level which was showing dose and duration of treatment. Maximum reduction of blood glucose was observed at day 28 (55.74%, 61.76% and 69.12% respectively). PF dose 500 mg/kg shown the maximum reduction of the high blood glucose level when compared to the two other different grades of doses of PF. On the other hand glibenclamide show the decreased level of blood glucose 65.27.

**Effect of PF of plasma insulin**

STZ treated group rat significantly decrease in serum insulin as compared to the normal control groups rat. Normal control rat received a PF dose (500 mg/kg) shown slightly improved the plasma insulin level as compared to the normal control group rat. STZ induced diabetic rat treated with different doses of PF significantly improved the plasma insulin level as compared to the diabetic control group rat (Table 2). On the all three graded doses, 500 mg/kg showed most significant improvement in decreasing the insulin level as compared to the diabetic control group rats.

**Effect of PF on glycated haemoglobin (A1c)**

Oral administration of different doses of PF was significantly decreased the level of glycated haemoglobin (A1c) in STZ-induced treated diabetic rats (Table 2). The level of glycated hemoglobin was normal in the wistar rats fed with normal diet (group I) in conjunction with the normal control rats received PF with a dose of 500 mg/kg (group II). STZ induced diabetic rat showed a marked increase in the level of glycated haemoglobin (A1c) in

---

**Table 1 Pharmacokinetic parameters of Paederia foetida Linn. extract in Oral glucose tolerance test**

| S. No | Pharmacokinetic parameters | Glucose control | Glucose + PF I (100 mg/kg) | Glucose + PF II (250 mg/kg) | Glucose + PF III (500 mg/kg) | Glucose + Glibenclamide (10 mg/kg) |
|-------|-----------------------------|-----------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------------|
| 1     | C\text{max} (mg/dl)        | 119.4           | 114.2                       | 110.2                       | 105.2                       | 107                               |
| 2     | t\text{max} (min)          | 30              | 30                          | 30                          | 30                          | 30                                |
| 3     | AUC (mg.min/dl)            | 16239           | 14847                       | 13929                       | 12645                       | 13020                             |

Each parameter represents the mean of Six animals. Area under curve (AUC) values. t\text{max}, time at maximum observed concentration; C\text{max}, maximum concentration.

---

*Figure 3 Oral glucose tolerance and AUC of PF leaves extracts in normal rats. Values are given as mean ± S.E.M. of six rats in each group. *p \leq 0.05, **p \leq 0.005, ***p \leq 0.001 compared with normal control values.*
STZ-induced treated diabetic rats. Upon the oral administration of the different doses of PF and glibenclamide significantly decrease the level of glycated haemoglobin as compared to the diabetic control.

**Effect of PF on hexokinase**

Hexokinase level was observed a decline in STZ treated group rat as compared to the normal control group (Table 2). Administration of PF dose 500 mg/kg in the normal rat showed little or no changes in the level of hexokinase. STZ induced diabetic rat treated with different doses of PF showed significant improvement in the degree of hepatic hexokinase. STZ induced diabetic rat treated with PF dose 500 mg/kg showed maximum improvement in the level of hexokinase as compared to the other graded dose and glibenclamide treated group rat.

**Effect of PF on glucose-6-phosphate**

It is the evident from the table that upon oral administration of STZ to wistar rats showed the increased level of glucose-6-phosphatase (Table 2). Oral administration of the PF dose 500 mg/kg did not show any change in the level of glucose-6-phosphatase. When STZ induced diabetic rat treated with different doses of PF, there was a significant (P < 0.001) decrease in the level of glucose-6-phosphatase in dose dependent manner. Upon administration of different doses of PF and Glibenclamide, significant (P < 0.001) decline in the level of glucose-6-phosphatase has been observed but the dose PF 500 mg/kg was found to be more effective to decline the high level of glucose-6-phosphatase.

**Effect of PF on fructose-1-6-biphosphatase**

The oral administration of PF dose 500 mg/kg has shown the equal level of fructose-1-6-biphosphatase compared to the normal control group rats. STZ induced diabetic rats significantly (P < 0.001) improved the level of fructose-1-6-biphosphatase as compared to the normal control group rat (Table 2). Upon oral administration of different doses of PF leaves extract and glibenclamide significantly (P < 0.001) decline the level of the fructose-1-6-biphosphatase. The PF dose 500 mg/kg showed the higher decline capability of fructose-1-6-biphosphatase as compared to the other dose of the PF and glibenclamide.

---

**Table 2 Effect of Paederia foetida Linn. on biochemical parameters in STZ-induced diabetic rats**

| S. No. | Biochemical parameter               | Normal control | Normal control + PF (500 mg/kg) | STZ-Diabetic control | STZ diabetes + PF I (100 mg/kg) | STZ diabetes + PF II (250 mg/kg) | STZ diabetes + PF III (500 mg/kg) | STZ diabetes + Glibenclamide (10 mg/kg) |
|--------|------------------------------------|----------------|---------------------------------|----------------------|---------------------------------|----------------------------------|----------------------------------|--------------------------------------|
| 1      | Fasting plasma glucose (mg/dL)     | 81.8 ± 0.201   | 79.8 ± 0.245                    | 348.4 ± 2.781        | 154.2 ± 1.812                   | 133.2 ± 0.861                    | 107.6 ± 1.749                     | 122 ± 1.844                         |
| 2      | Fasting Plasma Insulin (μU/mL)     | 11.4 ± 0.509   | 11.4 ± 0.245                    | 2.4 ± 0.453          | 4.2 ± 0.373                     | 6.2 ± 0.374                      | 10.6 ± 0.438                      | 9.6 ± 0.123                         |
| 3      | Glycated Haemoglobin (A1c) (%)     | 1.24 ± 0.092   | 1.24 ± 0.0812                   | 4.86 ± 0.178         | 3.96 ± 0.238                    | 2.82 ± 0.861                     | 1.52 ± 0.043                      | 1.86 ± 0.093                         |
| 4      | Hexokinase (μg/mg of tissue)       | 151 ± 3.24     | 150.6 ± 3.108                   | 88.4 ± 1.806         | 115.2 ± 1.497                   | 131 ± 1.643                      | 147.2 ± 1.281                     | 141.6 ± 2.088                        |
| 5      | Glucose-6-Phosphatase (unit/mg of tissue) | 8 ± 0.707 | 8 ± 0.717                     | 14.4 ± 0.927      | 13.4 ± 0.509                    | 11.4 ± 0.432                     | 8.4 ± 0.436                      | 9.8 ± 0.374                         |
| 6      | Fructose-1-6-biphosphatase (unit/mg of tissue) | 26.8 ± 1.241 | 27 ± 1.517                     | 54.8 ± 1.281        | 43 ± 1.871                      | 38.2 ± 1.497                     | 30 ± 0.707                      | 31 ± 0.431                          |
| 7      | Total Cholesterol (mg/dL)          | 66.2 ± 1.715   | 66.8 ± 1.393                    | 141.2 ± 2.634        | 129.8 ± 1.53                    | 101.8 ± 1.934                    | 76.2 ± 2.01                      | 84 ± 2.30                          |
| 8      | Triglycerides (mg/dL)              | 78 ± 1.975     | 78.2 ± 1.431                    | 144.8 ± 3.04         | 131 ± 1.789                     | 110.2 ± 1.828                    | 91 ± 1.703                       | 98 ± 1.265                         |
| 9      | Total HDL Cholesterol (mg/dL)      | 57 ± 1.14      | 57 ± 0.124                     | 25.4 ± 1.208         | 39 ± 1.223                      | 44.4 ± 1.03                      | 51.6 ± 0.927                    | 53.4 ± 0.927                        |
| 10     | Total LDL Cholesterol (mg/dL)      | 6.4 ± 0.18     | 6.8 ± 0.431                    | 86.8 ± 0.818         | 64.6 ± 0.053                    | 35.4 ± 0.538                     | 8.4 ± 1.12                      | 11 ± 0.742                         |
| 11     | Total VLDL Cholesterol (mg/dL)     | 15.6 ± 0.295   | 15.72 ± 0.132                  | 28.96 ± 0.608        | 26.2 ± 0.375                    | 22 ± 0.365                      | 18.2 ± 0.253                    | 10.6 ± 0.341                        |

Values are given as mean ± S.E.M. of six rats in each group. *P < 0.01* compared with the corresponding value for normal control animals (group 0); **P < 0.01** compared with the corresponding value for diabetic control animals (group III); ns-non significant.
Effect of PF on lipid profile

Effect of different doses of PF leaves extract on lipid profile level was evaluated. The level of cholesterol, triglyceride, LDL (low density cholesterol) and VLDL (very low density cholesterol) were increased and the level of HDL (high density cholesterol) was decreased in the STZ induced diabetic rat as compared to the normal control group rats. The oral administration of PF dose 500 mg/kg to the normal rat did not show any change in the lipid profile (Table 2). Oral administration of different doses (100 mg/kg, 250 mg/kg and 500 mg/kg, p.o.) of PF were showed percentage reduction in cholesterol (14.80%, 22.90%, 32.82%), triglyceride (11.48%, 21.07%, 33.72%), LDL (26.82%, 44.18%, 65.08%) and VLDL (11.48%, 21.07%, 33.72%), compared to the diabetic control rat group and the level of HDL (29.93%, 49.64%, 69.34%), was increased when compared to the diabetic control rat. Oral administration of PF dose 500 mg/kg showed the maximum benefit as compared to the other dose of the PF and glibenclamide in reducing the level of cholesterol, triglyceride, LDL cholesterol and VLDL cholesterol and increasing the level of HDL cholesterol as compared to the STZ induced diabetic control rat.

Changes in body weight

STZ treated diabetic rats showed significant loss the body weight as compared to the normal control group rat (Table 2). STZ treated diabetic control group rat significantly reduced the body weight as compared to the normal control group rats. STZ induced diabetic rat treated with different doses of PF (100 mg/kg, 250 mg/kg and 500 mg/kg) and glibenclamide (10 mg/kg) exhibited significant (P < 0.001) improvement in the body weight as compared to the diabetic control group rats.

Effect of PF on antioxidant enzymes

Table 3 represents the activity of the antioxidant enzyme like SOD, CAT, GPx and MDA in the normal and diabetic rat. The level of SOD, CAT, GPx decreased and MDA level increased in the STZ induced diabetic group rat (Table 3). Upon administration of PF with dose 500 mg/kg in the normal control group rat did not indicate any alteration in the level of antioxidant enzymes. Oral administration of different doses of PF (100 mg/kg, 250 mg/kg and 500 mg/kg) significantly improved the level of SOD, CAT, GPx and decline the level of MDA as compared to the normal control group rats. Oral administration of PF doses (100 mg/kg, 250 mg/kg and 500 mg/kg) brought to the value to near the normal, similar to the glibenclamide treated group rats.

Effect of PF on liver

STZ induced diabetic rat liver histopathology has shown the accumulation of fat droplet and large area of hepatocytes as compared to the histopathology of the normal control group rat liver histopathology. Oral administration of different doses of PF group rat showed the improved liver histopathology as compared to the diabetic control group rats (Figure 4). STZ induced diabetic rat treated with PF dose 100 mg/kg depicted the fat droplet accumulation in the liver as compared to the normal control groups rat but less than the diabetic control group rats. Other graded dose of PF 250 mg/kg showed the improved effect on the liver histopathology on the accumulation of the fat droplet as compared to the PF dose 100 mg/kg and diabetic control group rat. PF dose 500 mg/kg showed the systematic effect and did not show the any droplet of the fat accumulation on the liver histopathology as compared to the diabetic control. Glibenclamide treated group rat shown the liver histopathology similar to the normal control group rats (Figure 5).

Effect of PF on heart

STZ induced diabetic group rat disturbed the lipid profile and showed direct effect on the heart. Histopathology of heart showed the distorted intercalated discs and interstitial spaces, in STZ induced diabetic group

### Table 3 Effect of Paederia foetida Linn. on antioxidant marker in STZ-induced diabetic rats

| S. No. | Biochemical parameter | Normal control | Normal control + PF (500 mg/kg) | STZ-Diabetic control | STZ diabetes + PF I (100 mg/kg) | STZ diabetes + PF II (250 mg/kg) | STZ diabetes + PF III (500 mg/kg) | STZ diabetes + Glibenclamide (10 mg/kg) |
|-------|-----------------------|----------------|------------------------------|---------------------|-------------------------------|--------------------------------|---------------------------------|---------------------------------|
| 1     | SOD (U/mg of protein) | 7.8 ± 0.374 | 7.6 ± 0.245 | 2.2 ± 0.374 | 4.2 ± 0.374 | 5.2 ± 0.374 | 7.0 ± 0.316 | 6.6 ± 0.245 |
| 2     | CAT (U/mg of protein) | 72.1 ± 6.12 | 70.6 ± 1.72 | 38 ± 1.732 | 45.8 ± 1.06 | 53.8 ± 1.158 | 68 ± 1 | 65.4 ± 1.077 |
| 3     | GPx (nmole/ mg of protein) | 32.8 ± 1.02 | 32.6 ± 1.208 | 13.2 ± 0.37 | 19 ± 0.707 | 24.6 ± 0.509 | 31 ± 0.458 | 29.6 ± 0.927 |
| 4     | MDA (nmole/ mg of protein) | 0.2 ± 0.011 | 0.21 ± 0.007 | 0.54 ± 0.013 | 0.39 ± 0.009 | 0.32 ± 0.005 | 0.25 ± 0.005 | 0.26 ± 0.003 |

Values are given as mean ± S.E.M. of six rats in each group. *P < 0.01* compared with the corresponding value for normal control animals (group I); *P < 0.01* compared with the corresponding value for diabetic control animals (group III); ns-non significant.
rats (Figure 6). Now, the treatment with different doses of PF and glibenclamide showed the systematic effect on the heart histopathology. The distortion of intercalated discs was decline at dose dependent manner. The dose PF 500 mg/kg shown the histopathology of the heart almost similar to the normal heart. Glibenclamide treated group rat shown the histopathology similar to the normal control group rats (Figure 7).

**Effect of PF on kidney**

Histopathology of kidney was determined after 28 days treatment of different doses of PF and glibenclamide in STZ induced diabetic rats. Normal control group rat kidney histopathology showed the normal size of the bowman capsule and glomerulus. STZ induced diabetes rats’ kidney histopathology depicted the inflamed blood vessels, fat deposition, increase in the thickness of bowman capsules and
change in size of the glomerulus. Oral administration of different doses of PF reduced the inflammatory blood vessels. The treatment with PF 100 mg/kg dose showed the reduction of the inflammatory blood vessels and slightly shorter bowman capsules and glomerulus as compared to the diabetic control group rat kidney histopathology (Figure 8). Other PF dose 250 mg/kg kidney histopathology have shown the disappearance of the inflamed blood vessels and depicted the smaller size of the bowman capsules and glomerulus. PF dose 500 mg/kg caused complete disappearance of the inflamed blood vessel, but bowman capsule shown to be slightly bigger as compared to the normal control group rats. Glibenclamide treated group rat kidney histopathology did not show the any inflamed blood vessels and exhibiting the bowman capsules similar to the normal control group rat histopathology (Figure 9).

**Effect of PF on pancreas**

Histopathology studies of the experimental rat were measured after 28 days continuous administration of different
doses of PF and glibenclamide. STZ induced diabetic rat had shown the reduction of the isles of the Langerhans, reduced size of β cells and extensive necrosis changes followed by fibrosis and atrophy. Histopathology studies of pancreas of STZ induced diabetic rat displayed reduction of the islets of Langerhans, damaged or reduced size of β cells and extensive necrosis changes followed by fibrosis and atrophy (Figure 10). STZ induced diabetic rat treated with different doses of PF (100 mg/kg, 250 mg/kg, and 500 mg/kg) and glibenclamide restored the necrotic and fibrotic changes and raised the number of β cells (Figure 11).
Discussion

The present investigation study discusses about the anti-diabetic, antihyperlipidemic and antioxidant potential effect of the methanolic leaf extract of *Paederia foetida* Linn. in normal and streptozotocin induced diabetic rats. Phytochemical screening shows that the *Paederia foetida* Linn. Leaves extract consists the richest source of the various bioactive compounds. Acute toxicity studies of the *Paederia foetida* Linn. leaf extract reveals the non toxic nature of the extract at the dose upto 2000 mg/kg, there was no lethality or any other toxic reactions found with the selected dose until the conclusion of the study.

In the present study, STZ has been used as a diabetogenic agent to induce the diabetes in rodents. Low dose of STZ has been commonly used for the induction of type I diabetes (Insulin dependent diabetes mellitus). After treatment with low dose of STZ survival and regeneration of pancreatic β-cells is possible in type I diabetes [41]. Streptozotocin (2-deoxy-2-(N-methyl-N-nitrosourea) -1-D-glucopyranose) is a nitrosourea compound obtained from

---

**Figure 10 Paederia Foetida Linn. leaves extract effect on pancreas histopathology in normal and STZ induced diabetic rats.** (A) Normal control: Normal control group rat histopathology display the normal size of islet of langerhans (Green arrow) (B) Diabetic control: Diabetic control histopathology display the focal necrosis (yellow arrow) and bigger in the size of islets of langerhans (Black arrow). (C) PF I (100 mg/kg): PF tested drug display bigger size of islet (Black arrow) and focal necrosis (Yellow arrow). (D) PF II (250 mg/kg): PF tested drug display only focal necrosis (Yellow arrow) (E) PF III (500 mg/kg): PF tested drug display normal size of islet (Green arrow) (F) Glibenclamide (10 mg/kg): Glibenclamide treated rat pancreas showing normal islet (Green arrow). For each group 6 rats were examined and 50 pictures were taken. Original magnification, 10×.

---

**Figure 11 Paederia Foetida Linn. leaves extract effect on pancreas histopathology in normal and STZ induced diabetic rats.** (A) Normal control: Normal control group display the normal islet (Red arrow) (B) Diabetic control: Diabetic control rat histopathology display the islet enlargement (Blue arrow) and focal necrosis (Yellow arrow) (C) PF I (100 mg/kg): PF tested drug histopathology display bigger size of islet (Blue arrow) and focal necrosis (Yellow arrow) (D) PF II (250 mg/kg): Other PF tested drug display focal necrosis (Yellow arrow) and islet enlargement (Blue arrow). (E) PF III (500 mg/kg): PF tested drug display normal size of islet (Red arrow) (F) Glibenclamide (10 mg/kg): Glibenclamide treated group rat histopathology display normal islet (Red arrow) similar to the normal control group. For each group 6 rats were examined and 50 pictures were taken. Original magnification, 40×.
the soil microbe *Streptomyces achromogenes* [42], which is the potent alkylating agent that exerts its effect on the pancreatic β-cells via glucose transporter-GLUT2, causing induction of methylation of DNA and results in damage of DNA. Damaged DNA, activate the poly (ADP-Ribose) polymerase, leading to NAD⁺ depletion in pancreatic β-cells [43]. STZ also acts as a nitric oxide donor in pancreatic islets, enhances O₂⁻ radical fragmentation in islet cells. As a result, pancreatic β-cell death occurred by apoptosis and necrosis ensued, which in turn decreases proinsulin synthesis [44].

A lot of conventional drugs available in the market to cure and maintain the blood glucose level in diabetic patients. But most of the time sulfonylurea, such as glibenclamide has been used as a standard antidiabetic drug to compare the efficacy of a variety of antihyperglycemic compounds. Glibenclamide exerts their anti-diabetic action by stimulating insulin secretion. In our study, we have compared our plant based drug with the standard drug, Glibenclamide [45].

In the treatment of diabetes, there is a limited availability of the oral pharmacological agents. Now the current researches focus on the discovery of the novel oral pharmacological agents to control of blood glucose, hyperlipidemic and antioxidant with different mechanism of action. Allopathic medicines are widely available in the market to cure the diabetes but they are associated with the limitation due to their specific action and side effect. The best alternate to cure the diabetes is the alternative system of medicine which has a very long history. Plant derived antidiabetic agents are gaining popularity day by day at around the world for its effectiveness antidiabetic activity and minimal side effects [46].

In the subject field of the normolglycemic rats, *PF* showed the hypoglycaemic effect at dose dependent manner. In the study of the oral glucose tolerance test result showed the better utilization of the glucose by the animals. This plausible outcome that the different doses of the *PF* extract has the sound capacity to block glucose absorption. In the OGTT studies [34], it could be concluded that *PF* dose 500 mg/kg showed the maximum improvement in the glucose tolerance as compared to the other dose of *PF* and glibenclamide.

STZ induced diabetic rat increased the blood glucose level and decrease the insulin level due to STZ induced abnormalities in the β cell function [47]. The outcome of the case indicates that the methanolic leaf extract of *PF* restrained the blood sugar level in normoglycaemic, glucose-hypoglycaemic and STZ induced diabetic rats. In normoglycemic and STZ induced diabetic rats hypoglycaemic action of the *PF* leaf extract was observed at dose manner, with prolonged hypoglycaemic effect at higher dose. The *PF* dose, 500 mg/kg, is most effective to diminish the raised blood glucose level. The *PF* dose had shown the best result when compared to the synthetic drug glibenclamide (Table 2). The possible mechanism of activity of *PF* leaves extract may be stimulating the insulin secretion and regeneration of the β-cells of the pancreas or increasing cellularity of the islet tissue and regeneration of the granules in the β-cells. Based upon the result it can be hypothesized that *PF* declined the level of the blood glucose and improved the pancreas insulin level [45]. This hypothesis has been further confirmed by the histopathology studies of the pancreas which showed protection of the pancreas from the toxic effect of microbial streptozotocin (Figures 10 and 11). The leaf extract has shown the similar mechanism of action as glibenclamide, i.e. stimulating the insulin secretion.

In the STZ induced diabetes rats, reduced body weight was continuously observed. Body weight was continuously decreasing in the STZ induced diabetic rat due to muscle destruction or degeneration of structural proteins [48]. Normal rat and STZ induced diabetic rat treated with different doses of the *PF* leaves extract and glibenclamide, revealed body weight gain as compared to the diabetic control group rats. The result suggests that the different doses of the *PF* and glibenclamide shown the protective effect in the regulation of the muscle wasting (reversal of gluconeogenesis). Normal control group rat treated with *PF* dose, 500 mg/kg, has shown the better improvement in the body weight as compared to the diabetic control and normal control group rats (Table 2).

In normal condition, glycated hemoglobin make 3.4-5.8% of total hemoglobin and a small portion of blood glucose, usually 4.5-6%, has been covalently bonded to the red blood cells in hemoglobin. In diabetic condition increased level of the glycated hemoglobin due to increased level of blood glucose, which has been added to the N terminus of hemoglobin and producing the increased level of glycated hemoglobin [49]. In STZ induced diabetic condition glycated hemoglobin has been increased four times more than the normal level. Our result lie in agreement with this well known fact that treatment with *PF* for 28 days decreased the excess level of the glycated hemoglobin (Table 2), which indicates the improved echelon of glycemic control.

Some of the researcher claims that the oxidative stress plays an important role in the microvascular and macrovascular complication of diabetes [50]. In diabetes condition organ damage is the most common problem due to the defective cell antioxidant response against the oxidative stress generated in the diabetic condition [51]. Oxygen free radical plays an important role in the production of the oxidative stress. The free radical reacts with all biological substance, mainly polysaturated fatty acids and this reaction will lead to the cell membrane constituents lead to the lipid peroxidation [52]. During oxidative stress increased production of Lipid peroxidation impairs the
membrane function by decreasing membrane fluidity and changing the activity of membrane-bound enzyme and receptors [53]. These findings suggest that antioxidant treatment may be beneficial for diabetic patients. STZ induced diabetic rat increased the level of the antioxidant marker, several mechanisms of action are involved like overproduction of the free radical, glucose autooxidation, protein glycation, formation of advanced glycation products and polyol pathway [54]. In STZ induced diabetic condition increased level of the hepatic and renal MDA (as an indicator of the Lipid peroxidation) level and decreasing SOD, CAT, GPx level indicates the increased free radical generation. STZ induced diabetic rat treated with different doses of PF leaf extract decreased the level of MDA and improved the level of SOD, CAT and GPx. SOD is an important defense enzymatic antioxidant, the principal activity of the SOD is scavenge superoxide radical (O2-·) from to hydrogen peroxide (H2O2) and secondary action diminishes the toxic effects caused by the free radical reaction. The other enzymatic antioxidant CAT is a hemoprotein, which cause reduction of the hydrogen peroxide and known to be involved in the detoxification of hydrogen peroxide concentration [55]. The other antioxidant glutathione peroxidase has been able to reduce lipid hydroperoxide and hydrogen peroxide level. STZ induced diabetic rat with higher level of blood glucose can inactivate the SOD, CAT and GPx by fluctuating these proteins thus producing induced oxidative stress, which is turn, cause lipid peroxidation [56]. STZ induced diabetic rat treated with different doses of PF leaves extract brought back the level of SOD, CAT and GPx activities near to normal control group rat indicating the usefulness of PF in attenuating the oxidative stress in diabetic liver.

In the diabetes condition hypertriglyceridemia and hypercholesteremia are the common factors involved in the development of the atherosclerosis and coronary heart disease. This occurs due to lack of the insulin, which activates the lipase enzyme, hydrolyzed triglyceride (TG) and releasing the fatty acid and glycerol into the circulating blood. The level of the triglyceride has been increased in the STZ induced diabetic rat due to increased level of in-sulin, which causes failure to the activate lipoprotein lipase thereby causing hypertriglyceridemia [57]. STZ induced diabetes often involves abnormal lipid metabolism which is a metabolic disorder in diabetes complications [58]. In diabetes, increased level of total cholesterol, is one of the major factors for coronary heart disease (hyperlipidaemia) and its incidence of atherosclerosis. In our studies STZ induced diabetic rats have shown increased level of the total cholesterol. Treatment with the different doses of PF declines the highest level of total cholesterol and brought back the normal control level. The exact mode of action is unknown which involves the decline of total cholesterol. Decline in the cholesterol level achieved by the PF leaf extract has been shown to have direct effect on lipids or controlling the blood glucose level. LDL (Low density lipoprotein) and VLDL (Very low density lipoprotein) start depositing in the peripheral tissue in the diabetic condition [45], STZ induced diabetic rat increased the level of LDL and VLDL. The treatment has been started with different doses of PF leaf extract produces a decline in the higher level of LDL and VLDL cholesterol. On the other hand HDL (High density lipoprotein) cholesterol has been shown to decrease in the diabetic condition. Treatment with PF leaf extract for 28 days produces diminished level of TC, TG, LDL, and VLDL while the level of HDL Cholesterol has been significantly reduced [34]. These data suggest that the PF leaf extract possesses the excellent ability to ameliorate the lipid profile on the diabetic rats.

The liver plays an important role in the regulation of glucose metabolizing enzyme. Its regulate glucose-6-phosphatase, hexokinase and fructose-1-6-biphosphate. STZ induced diabetic rats have increased the level of glucose-6-phosphatase, which in turn enhance the production of fats from the carbohydrates results in increased level deposition of fats in the liver and kidney [59]. The deposition of the fats in the kidney and liver has been supported by the histopathological study. STZ induced diabetic rat treated with different doses of PF significantly decreased the level of glucose-6-phosphatase. Histopathological studies also supported the systematic effect of the PF extract at dose dependent manner. Fructose-1-6-biphosphatase is the other vital enzyme convert glucose into energy and plays an important role in the glycolysis [60,61]. STZ induced diabetic rats has been shown to have increased level of fructose-1-6-biphosphate. Treatment with PF leaves extract causes sharp decline in the higher level of fructose-1-6-biphosphate. Other liver enzyme hexokinase take part in the conversion of glucose into glucose-6-phosphatase and utilization of the glucose into the energy [62-65]. In STZ induced diabetic rats the collapse in glucose metabolism, disturb the capacity of the liver to synthesise glycogen, decline the level of hexokinase and decreased the use of energy. STZ induced diabetic rat treated with different doses of the PF leaf extract improved the level of hexokinase at dose dependent manner (Table 2).

Conclusion
In conclusion, our investigation has clearly indicated that the leaf extract of Paederia foetida Linn. showed remarkable antihyperglycemic activity due to its possible systematic effect involved in the pancreatic and extra pancreatic mechanism. Furthermore, the antihyperlipidemic activity was exerted by lowering the higher level of lipid profile and decreasing the intercalated disc space in the heart. The antioxidant activity of extract was due
to inhibition of lipid peroxidation and improved level of SOD, GPx and CAT. It was corroboratal that the extract of the Paederia foetida Linn leaves exhibited significant antidiabetic, antihyperlipidemic and antioxidant potential.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
VK premeditated and carried out the extraction of the Paederia foetida Linn leaves. VK, MM, DA, AV, AA, ZAD, PWR and PCB carried out the biochemical estimations. VK, VM and FA analyses the statistical data and interpretation of histological analysis. All the authors are involved in the critical evaluation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The present research was supported by the Department of the Pharmaceutical Sciences, Faculty of Health Sciences, SHIATS-Deemed University.

Author details
1Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom Institute of Agriculture, Technology & Sciences (SHIATS)-Deemed University, Allahabad, Uttar Pradesh 211007, India.
2Siddhartha Institute of Pharmacy, Dehradun, Uttrakhand, India.
3Health Information Technology Department, Jaddhah Community College, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia.
4Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
5Department of Pathology, MLN Medical College Allahabad, Allahabad, Uttar Pradesh, India.
6Department of Biological Sciences, Sam Higginbottom Institute of Agriculture, Technology & Sciences (SHIATS)-Deemed University, Allahabad, Uttar Pradesh, India.
7Department of Pharmacy & Pharmacognosy, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India.

Received: 11 November 2013 Accepted: 18 February 2014 Published: 25 February 2014

References
1. Ali O: Genetics of type 2 diabetes. World J Diabetes 2013, 4(6):114–123. 15.
2. Carpenter DO: Environmental contaminants as risk factors for developing diabetes. Rev Environ Health 2008, 23(1):59–75.
3. King H, Herman W: Global Burden of Diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21(9):1414–1431.
4. Ahmed D, Sharma M, Mukherjee A, Ramteke PW, Kumar V: Improved glycemic control, pancreas protective and hepatoprotective effect by total phytochemical fraction of Paederia foetida. J Ethnopharmacol 2004, 94:121–129.
5. Ramesh B, Pugalendi KV: Antidiabetic effect of umbelliferone in streptozotocin-diabetic rats. J Ethnopharmacol 2012, 143:515–523.
6. Bansal P, Paul P, Mudgal J, Nayak RG, Panarkal ST, Prayadasini K, Unnikrishnan MK: Antidiabetic, antihyperlipidemic and antioxidant effects of the flavonoid rich fraction of Pilea microphylla (L.) in high fat diet/streptozotocin-induced diabetic rats. BMC Complement Altern Med 2013, 13:10.
7. Ramesh B, Pugalendi KV: Antidiabetic and antioxidant activity of Toddalia asiatica (L.) Lam. Leaves in Streptozotocin induced diabetic rats. J Ethnopharmacol 2012, 143:515–523.
8. Nair P, Saini V, Sharma S, Nain J: Antidiabetic and antioxidant Potential of Emblica officinalis Gaertn. leaves extract in streptozotocin-induced type-2 diabetes mellitus(T2DM) rats. J Ethnopharmacol 2012, 142:65–71.
9. Deore AB, Sapaalk VD, Naikwade NS: Role of oxidative stress in pathogenesis of diabetes and its complications. Pharmacogonline 2011, 2:603–621.
10. Oberley LW, Oberley TD. Role of antioxidant enzymes in cell immortalization and transformation. Mol Cell Biochem 1986, 84(2):147–153.
11. Baynes JW, Rifai N: Oxidized low-density lipoprotein: A new active player in atherogenesis. Curr Opin Lipidol 1995, 6:373–380.
12. Marles RJ, Farnsworth NR: Antidiabetic plants and their active constituents. Phytomedicine 1995, 2:137–189.
13. Modak M, Dixit P, Londhe J, Ghaskadbi S, Desavagayam TP: Indian herbs and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr 2007, 40:163–173.
14. Orhan N, Aslan M, Demirci B, Ergun F: A bioactivity guided study on the antidiabetic activity of Juniperus oxycedrus subsp. oxycedrus L. leaves. J Ethnopharmacol 2012, 140:409–415.
15. The Ayurvedic Pharmacopeia of India; Part 1 (Vol – 1). New Delhi: Ministry of Health and Family Welfare Department and Indian System of Medicine and Homeopathy; 1999:137–140.
16. Kumar V, Yadav PKS, Singh UP, Bhat HR, Zaman MK, Ali M: Isolation of new racemic sugar (D/L galactaronic acid) from leaves of Paederia foetida Linn. Nature Preceding 2011. doi:10.1038/rep.
17. Ali O: Genetics of type 2 diabetes. World J Diabetes 2013, 4(6):114–123. 15.
18. Carpenter DO: Environmental contaminants as risk factors for developing diabetes. Rev Environ Health 2008, 23(1):59–75.
19. King H, Herman W: Global Burden of Diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21(9):1414–1431.
20. Ahmed D, Sharma M, Mukherjee A, Ramteke PW, Kumar V: Improved glycemic control, pancreas protective and hepatoprotective effect by total phytochemical fraction of Paederia foetida. J Ethnopharmacol 2004, 94:121–129.
21. Ramesh B, Pugalendi KV: Antidiabetic and antioxidant activity of Toddalia asiatica (L.) Lam. Leaves in Streptozotocin induced diabetic rats. J Ethnopharmacol 2012, 143:515–523.
22. Nair P, Saini V, Sharma S, Nain J: Antidiabetic and antioxidant Potential of Emblica officinalis Gaertn. leaves extract in streptozotocin-induced type-2 diabetes mellitus(T2DM) rats. J Ethnopharmacol 2012, 142:65–71.
23. Deore AB, Sapaalk VD, Naikwade NS: Role of oxidative stress in pathogenesis of diabetes and its complications. Pharmacogonline 2011, 2:603–621.
24. Oberley LW, Oberley TD. Role of antioxidant enzymes in cell immortalization and transformation. Mol Cell Biochem 1986, 84(2):147–153.
25. Hissin PJ, Hilf R: A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976, 69:364–371.
41. Daisy P, Jaiminea R, Ignacimuthu S, Murugan E: A novel Steroid1 from Elephas tus scaber L. an Ethno medicinal plant with antidiabetic activity. Phytomedicine 2009, 16:252–257.

42. Sithole HL: A review of the use of Streptozotocin (STZ) in the induction of diabetes in rats and subsequent ocular tissue changes. S Afr Optom 2009, 68(2):83–88.

43. Lee HW, Hakim P, Rabu A, Sani HA: Anti-diabetic, antioxidant and anti-hyperglycemic activities of Melastoma malabathricum Linn. leaves in streptozotocin induced diabetic rats. BMC Complement Altern Med 2013, 13:222.

44. Memis¸o˘gullar E, Bakan E: Antidiabetic activity of Caesalpinia bonducella seed extracts in rats. J Ethnopharmacol 2008, 115:173–183.

45. Manonmani G, Bhavapriya V, Kalpana S, Govindasamy S, Apparanantham T: Antidiabetic, antioxidant and anti-hyperglycemic activities of Melastoma malabathricum Linn. leaves in streptozotocin induced diabetic rats. BMC Complement Altern Med 2013, 13:222.

46. Krentz AJ: Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diab Obes Metab 2003, 5:519–527.

47. Lee HW, Hakim P, Rabu A, Sani HA: Antidiabetic, antioxidant and anti-hyperglycemic activities of Melastoma malabathricum Linn. leaves in streptozotocin induced diabetic rats. BMC Complement Altern Med 2013, 13:222.

48. Salahuddin M, Jalalpure SS: Antidiabetic activity of aqueous fruit extract of Cucumis trigonus Roxb. In streptozotocin induced diabetic rats. J Ethnopharmacol 2010, 127:565–567.

49. Klubier L, Molnar D, Kardos M, Jaszai V, Soltesz GY, Mestyan J: Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetologia 2003, 46:2170–2177.

50. Memit o’gullan R, Bakan E: Levels of ceruloplasmin, transferrin and lipid peroxidation in the serum of patients with type 2 diabetes mellitus. J Diabetes Complications 2004, 18:193–197.

51. Arulselvan P, Subramanian SP: Beneficial effects of Murraya koenigii leaves on antioxidant defense system and ultra structural changes of pancreatic β-cells in experimental diabetes in rats. J Biol Chem 2004, 279:519–527.

52. Latha M, Parimala V, Balaraman R: Antidiabetic and antihyperlipidemic effects of neem seed kernel powder on alloxan diabetic rabbits. Ind J Pharmaco 1997, 29:162–167.

53. Liu ZQ, Barrett EJ, Dalkin AC, Zwart AD, Chou JY: Antidiabetic effect of Cassia auriculata in streptozotocin induced diabetic rats. Fitoterapia 2013, 84:63–68.

54. West IC: Radicals and oxidative stress in diabetes. Diabet Med 2000, 17:171–180.

55. Kennedy AL, Lyons TJ: Glycation, oxidation and lipoxidation in diabetes. J Med Plants Res 2012, 6(5):796–812.

56. Fröde TS, Medeiros YS: Animal models to test drugs with potential antidiabetic activity. J Ethnopharmacol 2008, 115:173–183.

57. Arulselvan P, Subramanian SP: Beneficial effects of Murraya koenigii leaves on antioxidant defense system and ultra structural changes of pancreatic β-cells in experimental diabetes in rats. J Biol Chem 2007, 165:155–164.

58. Gold AH: The effect of diabetes and insulin on liver glycogen synthetase activation. J Biol Chem 1970, 245:903–905.

59. Raju J, Gupta D, Araga RR, Pramod KY, Baquer NZ: Trigonella foenum graecum (Fenugreek) seed powder improves glucose homeostasis in alloxan diabetic rats by reversing the altered glycolytic, gluconeogenic and lipogenic enzymes. Mol Cell Biochem 2001, 224:45–51.

Cite this article as: Kumar et al: Paederia foetida Linn. leaf extract: an antihyperlipidemic, antihyperglycaemic and antioxidant activity. BMC Complementary and Alternative Medicine 2014 14:76.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution